Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

369.82USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$369.82
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
278,610
52-wk High
$563.15
52-wk Low
$325.62

REGN.OQ

Chart for REGN.OQ

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company's segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the... (more)

Overall

Beta: 1.86
Market Cap(Mil.): $42,766.10
Shares Outstanding(Mil.): 105.47
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 59.06 42.21 29.87
EPS (TTM): 6.87 -- --
ROI: 15.46 -1.09 14.95
ROE: 20.48 -2.39 16.29

BRIEF-Regeneron entered into termination agreement relating to master terms and conditions for warrants

* On nov 14, entered into termination agreement relating to master terms and conditions for warrants, dated as of Oct 18, 2011

Nov 18 2016

No early win for Sanofi, Regeneron cholesterol drug in study

Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

Nov 17 2016

UPDATE 1-No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent, confounding hopes of some investors for an early win.

Nov 17 2016

No early win for Sanofi, Regeneron cholesterol drug in study

Nov 17 Sanofi and Regeneron Pharmaceuticals said on Thursday they would continue a large clinical outcomes study with their injectable cholesterol-lowering drug Praluent.

Nov 17 2016

BRIEF-Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting

* Regeneron Pharmaceuticals-In MONARCH study, sarilumab monotherapy showed superiority over adalimumab monotherapy in adults with active rheumatoid arthritis

Nov 16 2016

BRIEF-Regeneron and sanofi to present data from clinical trials

* Regeneron and Sanofi to present data from Phase 3 Praluent(alirocumab) injection clinical trials at AHA scientific sessions 2016 Source text for Eikon: Further company coverage:

Nov 11 2016

Regeneron profit tops Street on lower costs

Regeneron Pharmaceuticals Inc's quarterly profit handsomely beat estimates, helped by lower costs and a smaller tax bill, even as sales growth of its flagship drug Eylea continued to slow.

Nov 04 2016

UPDATE 4-Regeneron profit tops Street on lower costs

* Shares reverse course - up as much as 4.68 pct at $351.74 (Recasts, adds conf call details, updates shares)

Nov 04 2016

BRIEF-Regeneron CEO says Eylea rivals offering discounts, rebates: conf call

* Regeneron CEO says it is "early for us to comment on the expected timeline for potential sarilumab approval": conf call

Nov 04 2016

BRIEF-Regeneron Pharmaceuticals Q3 gaap EPS $2.27

* Regeneron reports third quarter 2016 financial and operating results

Nov 04 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF69.55 +0.05
Pfizer Inc. (PFE.N) $31.59 -0.04
Bayer AG (BAYGn.DE) €88.01 -0.14
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.44 -1.62
Merck & Co., Inc. (MRK.N) $60.25 -0.88
Amgen, Inc. (AMGN.OQ) $145.29 --
Roche Holding Ltd. (ROG.S) CHF223.80 +1.70
Roche Holding Ltd. (RO.S) CHF227.10 +1.10
Eli Lilly and Co (LLY.N) $67.26 -0.45

Earnings vs. Estimates